VENOGLOBULIN

Welfide Corporation

Application Filed: 2001-03-01
Trademark Application Details
Trademark Logo VENOGLOBULIN

Mark For: VENOGLOBULIN® trademark registration is intended to cover the categories of pharmaceutical preparations in the nature of gammaglobulin preparations for use in the treatment of primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplant in adults, chronic B-cell lymphocytic leukemia, pediatric HIV infection, chronic inflammatory demyelinating polyneuropathy, post-transfusion purpura, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneurophathy, anemia because of parvovirus B19, patients with stable multiple myeloma who are at high risk for recurrent infection, cytomegalovirus (CMV)-negative recipients of CMV-positive organs, hypogammaglobulinemic neonates with risk factor for infection or morbidity, intractable epilepsy, systemic vasculitic syndromes, warm-type automimmune hemolytic anemia, neonatal alloimmune thrombocytopenia when unresponsive to other treatments, immune-mediated neutropenia, decompensation in myasthenia gravis, dermatomyositis, polymyosits, thrombocytopenia when severe and unresponsive to other treatments. [all]

Status

2022-09-08 UTC
DEAD REGISTRATION Cancelled Invalidated
The trademark application was registered, but subsequently it was cancelled or invalidated and removed from the registry.


Research OneLook Acronym Finder
Serial Number76217836
Registration Number2717023
Mark Literal ElementsVENOGLOBULIN
Mark Drawing Type1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)
Mark TypeTRADEMARK
Standard Character ClaimNo
RegisterPRINCIPAL
Current LocationSCANNING ON DEMAND 2008-03-14
Basis1(a) 44(e)
Class StatusSECTION 8 - CANCEL
Primary US Classes
  • 006: Chemicals and Chemical Compositions
  • 018: Medicines and Pharmaceutical Preparations
  • 044: Dental, Medical and Surgical Appliances
  • 046: Foods and Ingredients of Foods
  • 051: Cosmetics and Toilet Preparations
  • 052: Detergents and Soaps
Primary International Class
  • 005 - Primary Class
  • (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed UseNo
Current UseYes
Intent To UseNo
Filed ITUYes
44D FiledNo
44E CurrentYes
66A CurrentNo
Current BasisNo
No BasisNo
Cancellation Code2
Domestic RepresentativeLynn A Sullivan
Attorney NameLynn A Sullivan
Law Office AssignedM60
Employee NameDEFORD, JEFFREY S

Timeline

1987-02-26Date of First Use
1987-02-26Date of Use In Commerce
2001-03-01Application Filed
2003-02-25Published
2003-02-25Published for Opposition
2003-05-20Trademark Registered
2008-03-14Location: SCANNING ON DEMAND
2009-12-26Cancelled
2009-12-26Status: Dead/Cancelled
2009-12-26Status: Registration cancelled because registrant did not file an acceptable declaration under Section 8. To view all documents in this
2018-07-08Transaction Date

Trademark Parties (Applicants & Owners)

Party: Welfide Corporation
Address6-9, Hiranomachi 2-chome Chuo-ku, Osaka-shi Osaka 541-0046 JAPAN
Legal Entity TypeCorporation
Legal Entity StateJAPAN

Documents

Application2001-03-01
Drawing2001-03-01
Paper Correspondence Incoming2001-11-16
Notice of PublicationAPPLICATION/XML2003-02-05
Registration Certificate2003-05-20
Registration Certificate2003-05-20
File Jacket2008-03-07
Specimen2008-03-07
Unclassified2008-03-07

Attorney of Record

LYNN A SULLIVAN
LEYDIG VOIT & MAYER LTD
TWO PRUDENTIAL PLAZA SUITE 4900
CHICAGO ILLINOIS 60601-6780

Good, Services, and Codes

(CANCELLED)
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations in the nature of gammaglobulin preparations for use in the treatment of primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplant in adults, chronic B-cell lymphocytic leukemia, pediatric HIV infection, chronic inflammatory demyelinating polyneuropathy, post-transfusion purpura, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneurophathy, anemia because of parvovirus B19, patients with stable multiple myeloma who are at high risk for recurrent infection, cytomegalovirus (CMV)-negative recipients of CMV-positive organs, hypogammaglobulinemic neonates with risk factor for infection or morbidity, intractable epilepsy, systemic vasculitic syndromes, warm-type automimmune hemolytic anemia, neonatal alloimmune thrombocytopenia when unresponsive to other treatments, immune-mediated neutropenia, decompensation in myasthenia gravis, dermatomyositis, polymyosits, thrombocytopenia when severe and unresponsive to other treatments. FIRST USE: 19870226. FIRST USE IN COMMERCE: 19870226

International Codes:5
U.S. Codes:006,018,044,046,051,052
Type CodeType
GS0051Pharmaceutical preparations in the nature of gammaglobulin preparations for use in the treatment of primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplant in adults, chronic B-cell lymphocytic leukemia, pediatric HIV infection, chronic inflammatory demyelinating polyneuropathy, post-transfusion purpura, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneurophathy, anemia because of parvovirus B19, patients with stable multiple myeloma who are at high risk for recurrent infection, cytomegalovirus (CMV)-negative recipients of CMV-positive organs, hypogammaglobulinemic neonates with risk factor for infection or morbidity, intractable epilepsy, systemic vasculitic syndromes, warm-type automimmune hemolytic anemia, neonatal alloimmune thrombocytopenia when unresponsive to other treatments, immune-mediated neutropenia, decompensation in myasthenia gravis, dermatomyositis, polymyosits, thrombocytopenia when severe and unresponsive to other treatments

Trademark Filing History

DescriptionDateProceeding Number
CANCELLED SEC. 8 (6-YR)2009-12-26
CASE FILE IN TICRS2008-03-14
REGISTERED-PRINCIPAL REGISTER2003-05-20
PUBLISHED FOR OPPOSITION2003-02-25
NOTICE OF PUBLICATION2003-02-05
USE AMENDMENT ACCEPTED2002-12-24
APPROVED FOR PUB - PRINCIPAL REGISTER2002-12-24
NON-FINAL ACTION MAILED2002-06-27
ASSIGNED TO EXAMINER2002-06-0675516
ASSIGNED TO EXAMINER2002-02-2575594
CORRESPONDENCE RECEIVED IN LAW OFFICE2001-11-16
NON-FINAL ACTION MAILED2001-10-29
AMENDMENT TO USE PROCESSING COMPLETE2001-10-17
CORRESPONDENCE RECEIVED IN LAW OFFICE2001-08-28
USE AMENDMENT FILED2001-07-02
CORRESPONDENCE RECEIVED IN LAW OFFICE2001-07-02
NON-FINAL ACTION MAILED2001-06-28
ASSIGNED TO EXAMINER2001-06-2774829

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed